We are growing closer to the time when our loved ones living with Rett syndrome will be able to communicate with us, to use their hands and to live a better life. Every day, researchers, doctors, nurses, families and funders are working together in relentless pursuit of the eradication of Rett syndrome. It is with pride that Rettsyndrome.org presents its 2017 Impact Report, highlighting what a committed and caring community can accomplish when the stakes are high.

In 2017, our training program has reached over 50 post-doctoral researchers ensuring a promising future for Rett syndrome research.

Continued expansion of our proprietary Scout Program yielded two compounds that will begin Phase 2 clinical trials in 2018.

FDA approval to launch the first Phase 3 trial for Rett syndrome studying trofinetide. Trial slated to begin in 2018.

Rettsyndrome.org 2016 advocacy efforts led Congress to add Rett syndrome as a 2017 topic of interest for the US Department of Defense and Congressionally Directed Medical Research Program. Dr. Colleen Niswender received $1.9 million dollars for drug discovery research.

As parents of a newly diagnosed one year old, we were given renewed hope when we read about the promising research trials on drugs like trofinetide and IGF-1. RSO has been vital to our getting through these first few months...

Lindsey Benjamin, mom to Leah age 1